HealthcareServices

Chronic Pruritus Therapeutics Industry Insights: Market Forecast to 2029

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Chronic Pruritus Therapeutics Market Size Likely To Evolve From 2025 Through 2034?

The chronic pruritus therapeutics market has witnessed substantial growth in recent years. It is anticipated to expand from $10.17 billion in 2024 to $10.91 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.3%. The growth observed in prior periods stems from factors such as the rising incidence of chronic pruritus, an increasing need for effective treatments, a growing number of regulatory approvals, an increase in product approvals, and a rise in mergers, collaborations, and acquisitions among industry participants.

The chronic pruritus therapeutics market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $14.36 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is driven by factors such as increasing awareness, a rise in atopic dermatitis cases, a growing emphasis on personalized medicine, the expanding prevalence of dermatological conditions, and an expanding patient demographic. Key trends defining this period encompass the introduction of new innovative medicines, the progress in developing novel biologics and targeted therapies, ongoing technological advancements, the incorporation of advanced drug delivery systems, strategic collaborations between pharmaceutical companies and research institutions, and the utilization of digital health technologies, including telemedicine.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Which Drivers Are Supporting Growth Of The Chronic Pruritus Therapeutics Market?

The increasing incidence of atopic dermatitis is anticipated to propel the expansion of the chronic pruritus therapeutics market going forward. Atopic dermatitis (AD) is a persistent inflammatory skin disorder characterized by redness, itching, dryness, and irritation, frequently affecting individuals with a familial background of allergies, asthma, or hay fever. The growing occurrence of atopic dermatitis can be attributed to multiple factors, such as genetic susceptibility, environmental shifts, lifestyle habits, the hygiene hypothesis, heightened exposure to allergens, and imbalances in the skin microbiome. Chronic pruritus therapeutics effectively alleviates the persistent itching associated with atopic dermatitis by targeting underlying inflammatory pathways, thus reducing skin irritation and improving patient comfort. For instance, in 2022, according to the International Eczema Council, a US-based nonprofit organization, approximately 223 million people globally were living with atopic dermatitis (GBD 2022), including 43 million children aged 1-4, which underscores the condition’s significant prevalence in early childhood. Hence, the rising prevalence of atopic dermatitis is driving the growth of the chronic pruritus therapeutics market.

What Are The Major Segments Identified In The Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeuticsmarket covered in this report is segmented –

1) By Product Type: Corticosteroid; Antihistamine; Local Anesthetic; Counterirritant; Immunosuppressant; Calcineurin Inhibitors; Other Product Types

2) By Disease Type: Atopic Dermatitis; Allergic Contact Dermatitis; Urticaria; Other Disease Types

3) By Distribution Channel: Hospital Pharmacies; Drug stores And Retail Pharmacies; Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines; Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics; Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants; Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants; Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy; Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies; Emerging Novel Therapies

What Key Innovation Trends Are Fueling Advancements In The Chronic Pruritus Therapeutics Market?

Key companies operating within the chronic pruritus therapeutics market are concentrating on developing innovative formulations, such as intravenous (IV) injections, to enhance treatment effectiveness and provide patients with faster relief. IV injections aid in treating pruritus by directly delivering medications, like antihistamines or corticosteroids, into the bloodstream to rapidly alleviate itching and reduce inflammation. For example, in September 2023, Cara Therapeutics Inc., a US-based company specializing in therapeutics, announced that its partner, Maruishi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, obtained approval from the Japan’s Ministry of Health, Labour and Welfare, a Japan-based government agency, for Korsuva IV injection syringe, designed to treat pruritus in hemodialysis patients. This authorization was granted following positive Phase 3 clinical trial results, which Maruishi conducted in collaboration with Kissei Pharmaceutical Co., Ltd. The treatment exhibited significant improvements in itching scores compared to a placebo and was well-tolerated by patients. Moreover, this approval triggers a $1.5 million milestone payment to Cara Therapeutics, the originator of Korsuva, as per the terms of their licensing agreement with Maruishi.

Which Global Market Leaders Are Shaping The Future Of The Chronic Pruritus Therapeutics Sector?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Region Is Projected To Lead The Chronic Pruritus Therapeutics Market During The Forecast Period?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Pruritus Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2025, By The Business Research Company

Chronic Myeloid Leukemia Cml Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Chronic Cough Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

Late Stage Chronic Kidney Disease Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795